Bevacizumab biosimilar(Guangdong Dongyangguang)

贝伐珠单抗生物类似药（广东东阳光）

Report date: 2022/03/15 18:06:11

Base Information

Drug NameBevacizumab biosimilar(Guangdong Dongyangguang)

Drug Alias NameRecombinant humanized anti-VEGF monoclonal antibody (Guangdong Dongyangguang)重组抗VEGF人源化单克隆抗体（广东东阳光）贝伐珠单抗生物仿制药（广东东阳光）贝伐单抗生物仿制药（广东东阳光）贝伐单抗生物类似药（广东东阳光） +[6]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesGuangdong Dongyangguang Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesGuangdong Dongyangguang Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell Lung

Inactive IndicationsN/A

Other Information

ATC CodeN/A